Navigation Links
Landmark ONTARGET(TM) Trial Demonstrates Micardis(R) is Equally Effective as Ramipril, with Fewer Discontinuations, in a Broad High-Risk Cardiovascular Population
Date:3/31/2008

ths," said Professor Salim Yusuf, lead investigator of the ONTARGET Trial Program and Director of the Population Health Research Institute at McMaster University, Hamilton, Canada. "The ONTARGET results have important implications for the management of patients with cardiovascular diseases."

In this trial, which was based on the HOPE study design, the benefits of telmisartan were demonstrated in a large group (8,542) of high-risk patients who were already receiving standard care such as statins to lower cholesterol, antiplatelet therapy, beta blockers and other antihypertensives.(3) Telmisartan treatment led to fewer discontinuations than treatment with ramipril, a widely used ACE inhibitor.(1) Although patients with an ACE inhibitor intolerance had been excluded from the trial, 360 (4.2 percent) patients in the ramipril treatment arm stopped their treatment because they experienced cough, a common ACE inhibitor side effect, versus only 93 (1.1 percent) patients in the telmisartan arm. Twenty-five patients stopped their treatment in the ramipril arm because of angioedema, versus only 10 in the telmisartan arm.(1) The incidence of hypotension was higher in the telmisartan arm (229 patients, 2.7 percent) versus the ramipril (149 patients, 1.7 percent) arm.(1)

"Boehringer Ingelheim is proud to have supported ONTARGET(TM), the largest cardiovascular outcomes trial of its kind and the first of a series of landmark clinical studies sponsored by our company. ONTARGET is just one example of Boehringer Ingelheim's leadership in trying to address the needs of people with cardiovascular disease," commented J. Martin Carroll, president and chief executive officer of Boehringer Ingelheim Pharmaceuticals, Inc. "We are committed to pursuing further research that evaluates ways to reduce the risk of damaging events in the heart, brain and other organs due to cardiovascular disease and to uncover new treatment strategies that may improve patient outcomes and care." '/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
2. Viatronix V3D-Colon Utilized in Another Landmark Study
3. Long-Term Data from a Landmark Phase III Trial Show Survival Benefit at Three- and Four-Years in Patients with Glioblastoma multiforme
4. Hospital Launches Landmark Emergency Medicine Project
5. JACC Identifies DEFER with 5-year Outcomes as Landmark Trial
6. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
7. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
8. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
9. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
10. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
11. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... -- Larry J. Merlo , President and CEO of ... the National Press Club in Washington, D.C. ... stop selling tobacco products and its leadership in driving the ... "Dramatic changes in our health care system pose enormous challenges ... said. "CVS Health has a truly unique combination of business ...
(Date:9/19/2014)... -- Alere Inc. (NYSE: ALR ), a global ... in support of President Barack Obama,s Executive ... leader in rapid diagnostics for infectious disease, we commend ... the serious threat of antibiotic resistance. We look forward ... to promote the development of rapid point-of-care tests that, ...
(Date:9/19/2014)... 19, 2014  Lpath, Inc. (NASDAQ: ... therapeutics, announced today that it has entered into ... common stock and 3,605,042 unregistered warrants in a ... one registered share of common stock and one ... common stock will be $3.475.  The warrants have ...
Breaking Medicine Technology:CVS Health CEO to Address National Press Club on Landmark Decision to Quit Tobacco, Leadership in Health Care Innovation 2CVS Health CEO to Address National Press Club on Landmark Decision to Quit Tobacco, Leadership in Health Care Innovation 3Alere Applauds President's Executive Order Combating Antibiotic-Resistant Bacteria 2Lpath, Inc. Announces $12.5 Million Registered Direct Offering 2Lpath, Inc. Announces $12.5 Million Registered Direct Offering 3
(Date:9/19/2014)... at Jacksonville,s campus of Mayo Clinic have discovered a ... to both overproduction of toxic protein in the brains ... loss of communication between neurons both significant contributors ... the online issue of Neuron , ... drugs "may rejuvenate or rescue this pathway," says the ...
(Date:9/19/2014)... FRIDAY, Sept. 19, 2014 (HealthDay News) -- When it ... deaths in the United States, while the District of ... Over the past decade, deaths from gun-related violence -- ... across the United States, the study revealed. Hawaii,s rate ... end of the spectrum, the District of Columbia had ...
(Date:9/19/2014)... Shahram Majidi, M.D., a second-year resident in ... University School of Medicine and Health Sciences, received ... to study the presence of diffuse brain swelling ... , "According to epidemiological studies, intracerebral hemorrhage accounts ... but is the least treatable form of stroke, ...
(Date:9/19/2014)... September 19, 2014 Top 10 ... recently announced that HostGator.com, GoDaddy and Bluehost are ... These companies are the most recommended suppliers for ... Europe to buy high quality Linux hosting (including ... ) is one of many top hosting companies ...
(Date:9/19/2014)... Capital Region Periodontics and Dental Implants, ... announce the latest addition to their treatment options ... needing dental implants. Often referred to as the ... fear factor normally associated with traditional gum surgery. ... make, this procedure a very attractive oral surgery ...
Breaking Medicine News(10 mins):Health News:Mayo researchers reveal pathway that contributes to Alzheimer's disease 2Health News:U.S. Gun Deaths Lowest in Hawaii, Highest in D.C. 2Health News:GW researcher receives grant to study brain swelling following bleeding in the brain 2Health News:Top10BestSEOHosting.com Announces Great Linux Web Hosting Suppliers In 2014 2Health News:Albany, NY Periodontist Reed Ference, DMD, Calms Fears of Patients with Gum Disease by Offering LANAP®, An Advanced, Less Invasive Treatment Solution 2Health News:Albany, NY Periodontist Reed Ference, DMD, Calms Fears of Patients with Gum Disease by Offering LANAP®, An Advanced, Less Invasive Treatment Solution 3
... in animal study , WEDNESDAY, Nov. 25 (HealthDay News) ... effectively as some synthetic drugs, English researchers report. , ... Hyptis crenata to treat a range of ... This study is the first to scientifically prove the ...
... , SAN FRANCISCO, Nov. 25 ... color cosmetics and advanced skin care dedicated to providing prestige ... prestige skin care and color cosmetic brand to launch under ... in San Francisco and Toronto, was founded and is managed ...
... ... , is launching a new website utilizing the latest internet technology to educate visitors ... media platforms to create an interactive web experience that’s designed to be an informative ... ...
... , WASHINGTON, Nov. 23 The American ... education, and media company, are launching "Explore the Mystery of ... the fields of science and medicine, in addition to exposing ... hematologists may remember watching a cartoon in grade school about ...
... ... Partner for Anthem Blue Cross, is working to raise awareness during the November 15 ... a zero-cost PPO Medicare Advantage plan. Freedom Blue PPO plans from Anthem Blue Cross ... ...
... radiation oncologists use advanced imaging techniques such as positron emission ... (4DCT) for target delineation (to locate the tumor and other ... in the December issue of the Journal of the ... ). In defining the target, the radiation oncologist draws ...
Cached Medicine News:Health News:Pari Beauty Professional Artistry 2Health News:Richmond, Virginia Plastic Surgeon Launches State-of-the-Art Breast Surgery Website 2Health News:Richmond, Virginia Plastic Surgeon Launches State-of-the-Art Breast Surgery Website 3Health News:Richmond, Virginia Plastic Surgeon Launches State-of-the-Art Breast Surgery Website 4Health News:New Science Program Teaches High School Students About Blood and Career Opportunities in the Field of Hematology 2Health News:New Science Program Teaches High School Students About Blood and Career Opportunities in the Field of Hematology 3Health News:BenefitPackages.com Reveals the Truth About No or Low Cost Medicare Supplement Plan Options Including Anthem Blue Cross Freedom Blue Regional PPO 2
...
Listeria Enrichment Broth...
1.7% Tryptone, 0.3% Soytone, 0.5% Sodium Chloride, 0.25% Dextrose, 0.25% Potassium Phosphate....
... accurately and conveniently controls the temperature at your ... temperature levels up to 99 C*, with the ... low as 5 C. The thermoblocks for 0.2 ... and microplates enable a high degree of flexibility ...
Medicine Products: